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Background: The current Canadian Cardiovascular Society antiplatelet
therapy guidelines recommend the use of ticagrelor or prasugrel over
clopidogrel as first-line platelet P2Y12 receptor antagonists for treat-
ment of moderate- to high-risk acute coronary syndromes. Recently,
Effient (prasugrel [Eli Lilly Canada Inc, Toronto, Canada]) was dis-
continued by its distributor in Canada.
Methods: Five members of the Canadian Cardiovascular Society an-
tiplatelet therapy 2018 guidelines committee undertook an indepen-
dent, evidence-based review to outline patients for whom prasugrel
should be the optimal P2Y12 agent and discuss alternative strategies
to consider without prasugrel.
Results: Several clinical scenarios where prasugrel should be indi-
cated are identified and discussed. Considerations to be undertaken
for alternative therapies are summarized, including a review of na-Received for publication October 28, 2020. Accepted November 18, 2020.
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Introduction : Dans ses lignes directrices actuelles sur la therapie
antiplaquettaire, la Societe canadienne de cardiologie recommande
l’utilisation du ticagrelor ou du prasugrel plutôt que l’utilisation du clo-
pidogrel comme antagonistes des recepteurs plaquettaires P2Y12 de
première intention dans le traitement des patients qui presentent un
risque modere à eleve de syndromes coronariens aigus. Depuis peu, le
distributeur a cesse la distribution d’Effient (prasugrel) au Canada.
Methodes : Cinq membres du comite des lignes directrices 2018 sur
la therapie antiplaquettaire de la Societe canadienne de cardiologie
ont entrepris une revue independante fondee sur les donnees pro-
bantes pour dresser le profil des patients pour lesquels le prasugrel
devrait être la meilleure option parmi les antagonistes des recepteurs
P2Y12 et se pencher sur les traitements alternatifs en l’absence de
prasugrel.Effient (prasugrel [Eli Lilly Canada Inc, Toronto, Canada]),
an oral P2Y12 platelet receptor inhibitor was discontinued
from the Canadian market on January 31, 2020, by its
distributor on the basis of a business decision. As 1 of only 2
first-line agents for acute coronary syndromes (ACS), this is
impactful for patient care in Canada and poses a therapeuticchallenge for clinicians, from family physicians to pharmacists,
internists, and cardiologists. This article delves into scenarios
in which prasugrel should be the optimal P2Y12 agent,
alternative strategies to consider without prasugrel, and
possible contributing factors for its discontinuation in
Canada.Background
Dual antiplatelet therapy using aspirin and a P2Y12
receptor antagonist is the cornerstone therapy after ACS and
percutaneous coronary intervention (PCI). Worldwide, there
are 4 available oral P2Y12 receptor inhibitorsdticlopidine,
clopidogrel, prasugrel, and ticagrelordof these, only the latter
3 are routinely used after ACS and PCI. Clopidogrel is thecular Society. This is an open access article under the CC BY-NC-ND license
tional and international guidelines for de-escalation of P2Y12 receptor
antagonists.
Conclusions: The discontinuation of prasugrel poses a challenge for
clinicians. Clinicians must consider key factors in determining the best
alternate therapy.
Resultats : Plusieurs scenarios cliniques où le prasugrel devrait être
indique sont recenses et abordes. Les reflexions sur les solutions de
rechange au traitement, notamment une revue des lignes directrices
nationales et internationales en matière de desescalade des antago-
nistes des recepteurs P2Y12, sont presentees.
Conclusions : La cessation de la distribution du prasugrel pose
problème aux cliniciens. Les cliniciens doivent tenir compte des
facteurs cles pour determiner le meilleur traitement de remplacement.
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disease. For ACS, ticagrelor and prasugrel have been shown in
large studies to be superior to clopidogrel in decreasing major
adverse cardiovascular events (MACE), at the cost of increased
bleeding complications.1,2 Canadian and international
guidelines endorse a preference of these 2 more potent P2Y12
drugs over clopidogrel as first-line in patients with ST-
elevation myocardial infarction and non-ST elevation ACS
at moderate to high risk of recurrent events; notably, a pref-
erence of prasugrel over ticagrelor post-PCI was endorsed in
the 2020 European Society of Cardiology non-ST elevation
ACS guidelines.3-6 In Canada, ticagrelor has been more
commonly prescribed than prasugrel. In several published
Canadian-based studies, the initial choice of prasugrel as the
first-line agent ranged from 0.4% to 12.5%; in contrast,
ticagrelor use in the same studies ranged from 11.1% to
36.4%.7-9 The underutilization might be attributed to several
possible factors.1,2 First, unlike ticagrelor, prasugrel has not
shown benefit over clopidogrel in those not undergoing
PCI.10 Second, ticagrelor demonstrated reduced cardiovascu-
lar mortality compared with clopidogrel in its pivotal trial;
whereas prasugrel’s benefit was driven by nonfatal events.
Third, prasugrel should not be used in patients with previous
transient ischemic attack or stroke; and a low 5-mg dose
(which was never available in Canada) should be used among
those age 75 years or older or with low body weight.3 Fourth,
patients in the , Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition With Prasugrel
Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38
study, with non-ST-elevation myocardial infarction, only
received prasugrel after anatomy was delineated at angiog-
raphy.2 In contrast, ticagrelor was given up front in the
Platelet Inhibition and Patient Outcomes (PLATO) trial1;
thus, making ticagrelor more applicable for physicians in non-
PCI centres, where patients might wait up to several days
before angiography.
Ticagrelor has practical challenges in a real-world setting,
including side effects, such as dyspnea, which might require
cessation or switching of medications. Drug interactions,
affecting ticagrelor pharmacodynamics, might also preclude its
use among patients with other medical conditions.11 Apropos
to guidelines and evidence from studies are that if a patient
cannot take a first-line agent, the default should be a change
between first-line agents, as opposed to a de-escalation to
clopidogrel.3,12 Ticagrelor and prasugrel have different
chemical structures and mechanisms of action; therefore
patients with allergy or intolerance can be switched safely
between agents.3,12
Notably, in the Intracoronary Stenting and Antith-
rombotic Regimen: Rapid Early Action for CoronaryTreatment 5 (ISAR-REACT 5) study, ticagrelor was evaluated
against prasugrel in a head-to-head open-label comparison in
patients with ACS and showed prasugrel superior in reducing
MACE.13 Because this study was relatively recent, its
findings likely did not influence Canadian physicians’ practice
patterns at the time of prasugrel’s withdrawal in Canada.Clinical Scenarios in Which Prasugrel Would Be
Clinically Indicated
I. Stent thrombosis or other thrombotic events during
treatment with ticagrelor
Although stent thrombosis among patients compliant with
ticagrelor is rare, it is documented in up to 0.8% undergoing
complex PCI.14 Although no clear evidence guides manage-
ment of patients with stent thrombosis during treatment with
ticagrelor, the 2018 Canadian Cardiovascular Society
antiplatelet guidelines do suggest consideration for a switch
between the agents, if technical considerations are ruled out.3
II. Patients experiencing sustained dyspnea due to
ticagrelor
The most frequent side effect of ticagrelor is dyspnea,
which does not affect pulmonary function.15 In a meta-
analysis, comprising 63,484 patients, ticagrelor was associ-
ated with substantially higher risk of dyspnea (relative risk ¼
2.65; 95% confidence interval, 1.87-3.76) as compared with
clopidogrel.16 Dyspnea from ticagrelor was reported in
13.8%-21.4% of participants randomized in trials necessi-
tating discontinuation of study drug in 0.9%-6.9%
(Table 1).1,17-20 Premature discontinuation of ticagrelor has
been reported in up to 25% of patients in real-life observa-
tional settings,21-23 most frequently related to dyspnea.24 In
the Prevention of Cardiovascular Events in Patients With
Prior Heart Attack Using Ticagrelor Tablets Compared to
Placebo on a Background of AspirineThrombolysis in
Myocardial Infarction 54) (PEGASUS-TIMI 54) trial, the 60-
mg and the 90-mg twice daily ticagrelor doses were associated
with higher rates of dyspnea and of premature discontinuation
of the study drug compared with placebo.17,18 A tendency
toward a higher rate of these events was observed with the 90-
mg twice daily dose compared with the 60-mg twice daily
dose, although no formal statistical comparison was
presented.17,18
III. Drug interactions with ticagrelor
Although ticagrelor is a direct-acting P2Y12 receptor
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Discontinuation of Prasugrel in Canadasubfamily A (CYP3A) enzymes to AR-C124910XX, an active
metabolite, before excretion.25 In a large observational patient-
level registry, 25% of patients initiating ticagrelor in the context
of ACSwere taking at least 1 potentially interacting drug.26 The
most common clinically relevant interactions were with
warfarin (3.8%) and nonsteroidal anti-inflammatory drugs
(0.4%-4.1%), both associated with increased bleeding risk.26
Interactions with serotonergic drugs, including antidepres-
sants, were also commonly reported (0.4%-1.7%).26 The
clinical importance of the interaction with selective serotonin
reuptake inhibitors is uncertain. No significant pharmacoki-
netic interaction was seen between ticagrelor and venlafaxine,
despite potential interaction via the cytochrome P450, family 2,
subfamily D, member 6 (CYP2D6) enzyme.27 A potential
increased cumulative risk of bleeding has been postulated, on
the basis of observational data with other antiplatelets.28 As
such, closer monitoring of patients taking these drugs is
reasonable, but their concurrent use does not preclude tica-
grelor initiation. Table 2 includes known clinically meaningful
drug interactions that affect ticagrelor. Concomitant use of
ticagrelor with potent CYP3A inducers, including phenytoin,
carbamazepine, and phenobarbital, have been shown to
potentiate ticagrelor metabolism and significantly reduce
platelet inhibition.11 In contrast, strong CYP3A inhibitors,
such as protease inhibitors, induce accumulation of ticagrelor,
leading to enhanced platelet inhibition and increased bleeding
risk.29,30 These drugs are encountered infrequently in patients
with ACS, although increased cardiometabolic risk in HIV-
positive patients compounded by adverse cardiometabolic ef-
fects of antiretroviral therapy might lead to more patients
requiring antiplatelet therapy for ACS.31
IV. Genetic considerations
Common CYP2C19 loss-of-function alleles, ranging from
25% to 40% depending on ethnic origins, affect clopidogrel
metabolism and put carriers at risk for ischemic complications
after PCI.32 Prasugrel and ticagrelor mitigate ischemic risks
among patients with these genetic variants.32,33 The Phar-
macogenetics of Clopidogrel in Patients With Acute Coro-
nary Syndromes (PHARMCLO) and POPular Genetics
studies had both evaluated a pharmacogenomic approach, in
which carriers of at-risk alleles were treated with ticagrelor or
prasugrel, while noncarriers received clopidogrel.34,35
Compared with standard of care per physicians’ discretion,
the former study showed a reduction in the composite pri-
mary end point of ischemic and bleeding outcomes; the latter
showed pharmacogenomics to be noninferior for ischemic
complications, but reduced bleeding. In a post hoc analysis of
the recent Tailored Antiplatelet Initiation to Lessen Out-
comes Due to Decreased Clopidogrel Response After Percu-
taneous Coronary Intervention (TAILOR-PCI) trial, a
genotype-guided approach in the first 3 months post PCI
showed a reduction in ischemic outcomes.36 For patients
known to be carriers of loss-of-function variants and intol-
erant of ticagrelor, prasugrel treatment remains the reasonable
first choice.
V. Patients with issues of nonadherence
Adherence to taking P2Y12 inhibitors is an important
determinant of efficacy, with lower rates of compliance being
Table 2. Selected drug interactions with ticagrelor
Drugs
Effect when coadministered with
ticagrelor Precautions References




parameters, leading to reduced
ticagrelor bioavailability and half-life
Reduced platelet inhibition on
ticagrelor
11,47




parameters, leading to potential
accumulation









Closer monitoring of P-glycoprotein
transporter substrates with a narrow
therapeutic window upon ticagrelor
initiation
49
CYP3A, cytochrome P450, family 3, subfamily A.
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Volume - 2021associated with MACE. In a large cohort of 55,340
commercially insured patients, ticagrelor had significantly
lower long-term adherence than clopidogrel.37 The reasons for
nonadherence are multisystemic,38 but the twice-daily dosing
of ticagrelor compared with prasugrel and clopidogrel might
play a role; thus, it is a potential consideration in choosing
P2Y12 inhibitors for patients, when medication adherence
might be a concern.Table 3. Guidance for P2Y12 inhibitor therapy without prasugrel
Dyspnea/intolerance to ticagrelor Drug inter
< 7 Days from
ACS/PCI
Options:
(1) Persist with ticagrelor and reassess
on the basis of symptoms;
(2) High-dose clopidogrel 150 mg
daily for 7 days (preceded by 600
mg bolus dose) then 75 mg daily*;
(3) Consider compassionate release of
prasugrel in high-risk patients in
whom clopidogrel is not a good
option;












(1) Persist with ticagrelor and reassess
based on symptoms;
(2) De-escalate to clopidogrel (see
Fig. 1);
(3) Consider compassionate release of
prasugrel in high-risk patients in
whom clopidogrel is not a good
option;









> 30 Days Options:
(1) Persist with ticagrelor and reassess;
(2) De-escalate to clopidogrel (see
Fig. 1);
(3) Consider compassionate release of
prasugrel in high-risk patients in
whom clopidogrel is not a good
option;









All suggested therapies are on the basis of expert opinions and extrapolation of
ACS, acute coronary syndromes; GLOBAL LEADERS, Ticagrelor Plus Aspiri
Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention
OASIS 7, Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events-
coronary intervention, TWILIGHT, Ticagrelor With Aspirin or Alone in High-Ris
* Per CURRENT-OASIS 7.
y Per TWILIGHT study if after 3 months, or GLOBAL LEADERS study afterConsiderations for Selecting Alternative
Strategies
Discontinuation of Effient from the Canadian market
unveils a gap in clinical management of high-risk patients,
early after ACS or complex PCI. Two important factors must
be considered concurrently in determining the safest course in
patients who might benefit from more intensive P2Y12
inhibition, but for whom ticagrelor is not an option. The firstactions with ticagrelor Major bleeding or high bleeding risk
clopidogrel 150 mg daily
(preceded by 600 mg bolus
75 mg daily*;




idogrel is not a good option
Options:
(1) De-escalate to clopidogrel (see Fig. 1).
Consider resuming ticagrelor if cause
of bleeding resolved;
(2) Consider aspirin interruption or
cessation if bleeding or high bleed risk
to clopidogrel (see Fig. 1);




idogrel is not a good option
Options:
(1) De-escalate to clopidogrel (see Fig. 1).
Consider resuming ticagrelor if cause
of bleeding resolved;
(2) Consider aspirin interruption or
cessation if bleeding or high bleed risk
to clopidogrel (see Fig. 1);




idogrel is not a good option
Options:
(1) De-escalate to clopidogrel (see Fig. 1);
(2) Aspirin cessation with ticagrelor mon-
otherapy if bleed risk high, but no
active bleedingy
best evidence.
n Followed by Ticagarelor Monotherapy vs a Current-Day Intensive Dual
With Bivalirudin and Biomatrix Family Drug-Eluting Stents; CURRENT-
Organization to Assess Strategies in Ischemic Syndromes 7; PCI, percutaneous
























































Loading dose: Clopidogrel 600 mg
Maintenance dose: 75 mg daily
Timing: at the next scheduled 
cagrelor dose *
* Extending to 24h post last cagrelor dose also reasonable
Loading dose: Clopidogrel 300 - 600 mg (oponal)
Maintenance dose: 75 mg daily
Timing: at the next scheduled 
cagrelor dose *
Loading dose: Clopidogrel 600 mg
Maintenance dose: 75 mg daily
Timing: 24h aer last cagrelor dose 
Loading dose: Clopidogrel 600 mg
Maintenance dose: 75 mg daily
Timing: 24h aer last cagrelor dose 
Late / chronic
Consider doubling the maintenance 
dose of clopidogrel to 150 mg daily 
in the first week post-ACS
Early / acute
up to 30 days
Figure 1. Overview of de-escalation strategies from ticagrelor to clopidogrel in the Canadian, European, and international guidance documents. The
orange box is an additional consideration from this group. The early period covers up to 30 days after the acute coronary event. ACS, acute coronary
syndromes.
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Discontinuation of Prasugrel in Canadais timing from index ACS or PCI, because those within the
first few days or weeks are at highest risk for ischemic com-
plications. The second is the reason underlying the switch.
Strategies for those with bleeding will be inherently different
to those with intolerances or other rationale. Because prasugrel
is associated with increased major bleeding relative to clopi-
dogrel, a switch to prasugrel when bleeding is a concern would
not be considered appropriate. Intuitively, serious bleeding
concerns in high-risk patients will favour a de-escalation to
clopidogrel or to single antiplatelet therapy (SAPT), whereas
intolerance or nonadherence would favour alternative potent
P2Y12 regimens. With these 2 factors accounted, possible
solutions are presented in Table 3. Figure 1 further summa-
rizes Canadian, European, and international guidelines on
safest means to switching from ticagrelor to clopidogrel if it is
deemed required.
Alternative clopidogrel regimen
High-dose clopidogrel during the first week after PCI
minimizes ischemic complications in patients early after ACS.
This approach, studied in Clopidogrel and Aspirin Optimal
Dose Usage to Reduce Recurrent Events-Organization to
Assess Strategies in Ischemic Syndromes (CURRENT-
OASIS) 7, showed doubling clopidogrel loading (600 mg) and
maintenance doses (150 mg daily) for 1 week after ACS
treated with PCI was associated with a diminution of
MACE.39 The reduction in the rate of stent thrombosis with
double-dose clopidogrel was 31%, which was similar to the
effect of ticagrelor in PLATO (25% reduction).1,2 In the
Escalating Clopidogrel by Involving a Genetic Strategy -
Thrombolysis in Myocardial Infarction 56 (ELEVATE-TIMI56) trial, high maintenance clopidogrel doses of 225 mg daily
in heterozygous carriers of CYP2C19 loss-of-function alleles
yielded similar levels of platelet inhibition compared with
standard 75 mg in noncarriers.40 However, the effect of a
genotype-guided dosing strategy for clopidogrel as
replacement for ticagrelor after ACS and PCI on outcomes
has not been studied and is not routinely recommended
clinically.
Reduced-dose ticagrelor
Lowering ticagrelor dose from 90 mg to 60 mg to decrease
side effects is theoretically attractive, on the basis of
pharmacodynamic data showing 60 mg achieving similar
platelet inhibition, and a numerical reduction in major
bleeding and incidence of dyspnea.17,41 However, this dose
has not been evaluated in the early ACS setting. Additionally,
rates of discontinuation for side effects compared with a 90-
mg dose were not statistically different in PEGASUS-TIMI
56.17
SAPT with ticagrelor
Bleeding has been reported as the reason for stopping
ticagrelor in up to 30% with premature discontinuation.18,25
In the Ticagrelor With Aspirin or Alone in High-Risk Pa-
tients After Coronary Intervention (TWILIGHT) and Tica-
grelor Monotherapy After 3 Months in the Patients Treated
With New Generation Sirolimus Stent for Acute Coronary
Syndrome studies, a strategy of ticagrelor monotherapy vs dual
antiplatelet therapy was evaluated in patients 3 months after
ACS or complex PCI.14,42 A reduction of clinically relevant
6 CJC Open
Volume - 2021bleeding and no differences in MACE were reported, sug-
gesting early SAPT with ticagrelor alone may be considered
among patients with bleeding risk or those with actionable,
but not major bleeding.
De-escalation to clopidogrel
Clopidogrel had been the standard of care before arrival of
more potent P2Y12 inhibitors. De-escalation to clopidogrel
14-30 days after the index event was investigated in the
Timing of Platelet Inhibition After ACS (TOPIC) and
Testing Responsiveness to Platelet Inhibition on Chronic
Antiplatelet Treatment for Acute Coronary Syndromes
(TROPICAL-ACS) trials, suggesting noninferiority of these
approaches vs maintaining more intensive P2Y12 therapies
long-term.43,44 In the Ticagrelor or prasugrel versus clopi-
dogrel in elderly patients with an acute coronary syndrome:
optimization of antiplatelet treatment in patients aged older
than 70 years (POPular AGE) study, clopidogrel was shown
to be a reasonable alternative to ticagrelor in patients older
than the age of 70 years, mainly because of reductions in
bleeding risk.45 Thus, use of clopidogrel is acceptable in
patients with higher bleeding risk and lower thrombotic risk.
Limited access to prasugrel
For patients with stent thrombosis during ticagrelor
treatment, when prasugrel might be integral and alternate
strategies might put them at risk, there are mechanisms to
apply for compassionate release, with prasugrel importation
from other countries. Unfortunately, evaluation on a patient-
by-patient basis renders the process unpredictable. On a long-
term basis, a generic form of prasugrel would be required to
bridge the gap in clinical care. Although approval is under
way, as yet generic formulations are not available in Canada.Conclusion
Despite evidence of superiority in ACS,2,13 prasugrel was
not able to garner a large market share in Canada; this likely
being the primary reason for its discontinuation from the Ca-
nadian market. We can postulate on potential contributors to
the lower uptake in clinical practice, including a higher risk of
major and life-threatening bleeding, lack of reduction in mor-
tality compared with clopidogrel, lack of benefit over clopi-
dogrel in ACS patients managedmedically, unavailability of the
5-mg dosing, and limitations in the generalizability of the
pivotal trial establishing the benefit of prasugrel. Additionally,
loss of patent protection might also have provided impetus for
the drug’s discontinuation by its distributor. Indeed, the deci-
sion to stop supplying Effient was announced 1 year after an
unsuccessful attempt to protect its Canadian patent on a
combination of prasugrel and aspirin in 2018.46 In retrospect, it
is easy to identify areas in which prasugrel was likely underu-
tilized. For example, in high-risk patients with side effects or
drug interactions to ticagrelor, prasugrel should have been the
evidence-based second choice. Data from ISAR-REACT 5,13
coupled with the newly revised European guidelines’ prefer-
ence of prasugrel over ticagrelor,6 would support its role in our
arsenal of P2Y12 inhibitors. If generic prasugrel becomes
available, it might be an opportunity for physicians to re-
examine the evidence for its use in higher-risk patients.Funding Sources
M.L. is a Canada Research Chair in Platelets as vectors and
biomarkers. J.-F.T. is supported by the Desgroseillers-Berard
Research Chair in Interventional Cardiology at the Universite
de Montreal. D.Y.F.S. is supported by a Mid-Career Inves-
tigator Award of the Heart and Stroke Foundation of Ontario.Disclosures
M.L. has received speaker honoraria from Bayer; has
received research grants to the institution from Idorsia; has
served on a national advisory board for Servier; and
has received in-kind and financial support for investigator-
initiated grants from Leo Pharma, Roche Diagnostics,
Aggredyne, and Fujimori Kogyo. G.M.-G. has received hon-
oraria from Servier and Novartis (unrelated to this work). J.-
F.T. has received research grants to the institution from
Abbott Vascular, Biosensors, Idorsia, and Novartis; is a
member of advisory boards for Bayer Canada, Daichii-
Sankyo, Novartis, and Servier; has received speaker honorar-
ia from Astra-Zeneca, Bayer Canada, BMS-Pfizer Alliance,
and Servier. S.R.M. has received research grants from Astra
Zeneca Canada. D.Y.F.S. has received unrestricted grant
support (physician-initiated grant) from Eli Lilly Canada; is a
member of the advisory board and has received honoraria
from AstraZeneca Canada; is a member of the advisory board
for Bayer Canada; has received unrestricted grant support
(physician-initiated grant) from Spartan Biosciences; has
received unrestricted grant support (physician-initiated grant)
from Aggredyne; has received unrestricted grant support
(physician-initiated grant) from Diapharma/Roche
Diagnostics; and has received honoraria from Abbott
Vascular, Canada.
References
1. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in
patients with acute coronary syndromes. N Engl J Med 2009;361:
1045-57.
2. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus
clopidogrel in patients with acute coronary syndromes. N Engl J Med
2007;357:2001-15.
3. Mehta SR, Bainey KR, Cantor WJ, et al. 2018 Canadian Cardiovascular
Society/Canadian Association of Interventional Cardiology focused up-
date of the guidelines for the use of antiplatelet therapy. Can J Cardiol
2018;34:214-33.
4. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused
update on duration of dual antiplatelet therapy in patients with coronary
artery disease: a report of the American College of Cardiology/American
Heart Association Task Force on Clinical Practice Guidelines. J Am Coll
Cardiol 2016;68:1082-115.
5. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on
dual antiplatelet therapy in coronary artery disease developed in
collaboration with EACTS: the Task Force for dual antiplatelet therapy in
coronary artery disease of the European Society of Cardiology (ESC) and
of the European Association for Cardio-Thoracic Surgery (EACTS). Eur
Heart J 2018;39:213-60.
6. Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the
management of acute coronary syndromes in patients presenting without
persistent ST-segment elevation. Eur Heart J 2021;42:1289-367.
Lordkipanidze et al. 7
Discontinuation of Prasugrel in Canada7. Welsh RC, Sidhu RS, Cairns JA, et al. Outcomes among clopidogrel,
prasugrel, and ticagrelor in ST-elevation myocardial infarction patients
who underwent primary percutaneous coronary intervention from the
TOTAL trial. Can J Cardiol 2019;35:1377-85.
8. Dery JP, Mehta SR, Fisher HN, et al. Baseline characteristics, adenosine
diphosphate receptor inhibitor treatment patterns, and in-hospital
outcomes of myocardial infarction patients undergoing percutaneous
coronary intervention in the prospective Canadian Observational
AntiPlatelet sTudy (COAPT). Am Heart J 2016;181:26-34.
9. Turgeon RD, Koshman SL, Youngson E, et al. Association of ticagrelor
vs clopidogrel with major adverse coronary events in patients with acute
coronary syndrome undergoing percutaneous coronary intervention.
JAMA Intern Med 2020;180:420-8.
10. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for
acute coronary syndromes without revascularization. N Engl J Med
2012;367:1297-309.
11. Pourdjabbar A, Hibbert B, Chong AY, et al. A pharmacodynamic analysis
for the co-administration of inducers of CYP3A with ticagrelor: a
cautionary tale in managing patients with acute coronary syndromes. Int
J Cardiol 2016;214:423-5.
12. Angiolillo DJ, Rollini F, Storey RF, et al. International expert consensus
on switching platelet P2Y12 receptor-inhibiting therapies. Circulation
2017;136:1955-75.
13. Schupke S, Neumann FJ, Menichelli M, et al. Ticagrelor or prasugrel in
patients with acute coronary syndromes. N Engl J Med 2019;381:
1524-34.
14. Dangas G, Baber U, Sharma S, et al. Ticagrelor with or without aspirin
after complex PCI. J Am Coll Cardiol 2020;75:2414-24.
15. Storey RF, Bliden KP, Patil SB, et al. Incidence of dyspnea and assess-
ment of cardiac and pulmonary function in patients with stable coronary
artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/
OFFSET study. J Am Coll Cardiol 2010;56:185-93.
16. Zhang N, Xu W, Li O, Zhang B. The risk of dyspnea in patients treated
with third-generation P2Y12 inhibitors compared with clopidogrel: a
meta-analysis of randomized controlled trials. BMC Cardiovasc Disord
2020;20:140.
17. Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in
patients with prior myocardial infarction. N Engl J Med 2015;372:
1791-800.
18. Bonaca MP, Bhatt DL, Oude Ophuis T, et al. Long-term tolerability of
ticagrelor for the secondary prevention of major adverse cardiovascular
events: a secondary analysis of the PEGASUS-TIMI 54 trial. JAMA
Cardiol 2016;1:425-32.
19. Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in patients with stable
coronary disease and diabetes. N Engl J Med 2019;381:1309-20.
20. Jones WS, Baumgartner I, Hiatt WR, et al. Ticagrelor compared with
clopidogrel in patients with prior lower extremity revascularization for
peripheral artery disease. Circulation 2017;135:241-50.
21. Arora S, Shemisa K, Vaduganathan M, et al. Premature ticagrelor
discontinuation in secondary prevention of atherosclerotic CVD: JACC
review topic of the week. J Am Coll Cardiol 2019;73:2454-64.
22. Zeymer U, Cully M, Hochadel M. Adherence to dual antiplatelet therapy
with ticagrelor in patients with acute coronary syndromes treated with
percutaneous coronary intervention in real life. Results of the REAL-
TICA registry. Eur Heart J Cardiovasc Pharmacother 2018;4:205-10.23. Zanchin T, Temperli F, Karagiannis A, et al. Frequency, reasons, and
impact of premature ticagrelor discontinuation in patients undergoing
coronary revascularization in routine clinical practice: results from the
Bern Percutaneous Coronary Intervention Registry. Circ Cardiovasc
Interv 2018;11:e006132.
24. Bergmeijer TO, Janssen PWA, van Oevelen M, et al. Incidence and
causes for early ticagrelor discontinuation: a “real-world” Dutch registry
experience. Cardiology 2017;138:164-8.
25. Biscaglia S, Tonet E, Pavasini R, et al. A counseling program on nuisance
bleeding improves quality of life in patients on dual antiplatelet therapy: a
randomized controlled trial. PLoS One 2017;12:e0182124.
26. Prami T, Khanfir H, Hasvold P, et al. Concomitant use of drugs known
to cause interactions with oral antiplatelets-polypharmacy in acute cor-
onary syndrome outpatients in Finland. Eur J Clin Pharmacol 2020;76:
257-65.
27. Teng R, Kujacic M, Hsia J. Evaluation of the pharmacokinetic interac-
tion between ticagrelor and venlafaxine, a cytochrome P-450 2D6
substrate, in healthy subjects. Clin Ther 2014;36:1217-25.
28. Andrade C, Sharma E. Serotonin reuptake inhibitors and risk of
abnormal bleeding. Psychiatr Clin North Am 2016;39:413-26.
29. Teng R, Butler K. Effect of the CYP3A inhibitors, diltiazem and keto-
conazole, on ticagrelor pharmacokinetics in healthy volunteers. J Drug
Assess 2013;2:30-9.
30. Marsousi N, Samer CF, Fontana P, et al. Coadministration of ticagrelor
and ritonavir: toward prospective dose adjustment to maintain an optimal
platelet inhibition using the PBPK approach. Clin Pharmacol Ther
2016;100:295-304.
31. Grinspoon SK, Douglas PS, Hoffmann U, Ribaudo HJ. Leveraging a
landmark trial of primary cardiovascular disease prevention in human
immunodeficiency virus: introduction from the REPRIEVE Coprincipal
Investigators. J Infect Dis 2020;222:S1-7.
32. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic
polymorphisms and the response to prasugrel: relationship to pharma-
cokinetic, pharmacodynamic, and clinical outcomes. Circulation
2009;119:2553-60.
33. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1
single nucleotide polymorphisms on outcomes of treatment with
ticagrelor versus clopidogrel for acute coronary syndromes: a genetic
substudy of the PLATO trial. Lancet 2010;376:1320-8.
34. Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided
strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med
2019;381:1621-31.
35. Notarangelo FM, Maglietta G, Bevilacqua P, et al. Pharmacogenomic
approach to selecting antiplatelet therapy in patients with acute coronary
syndromes: the PHARMCLO trial. J Am Coll Cardiol 2018;71:1869-77.
36. Pereira NL, Farkouh ME, So D, et al. Effect of genotype-guided oral
P2Y12 inhibitor selection vs conventional clopidogrel therapy on
ischemic outcomes after percutaneous coronary intervention: the
TAILOR-PCI randomized clinical trial. JAMA 2020;324:761-71.
37. Dayoub EJ, Seigerman M, Tuteja S, et al. Trends in platelet adenosine
diphosphate P2Y12 receptor inhibitor use and adherence among
antiplatelet-naive patients after percutaneous coronary intervention,
2008-2016. JAMA Intern Med 2018;178:943-50.
38. Lauffenburger JC, Choudhry NK. A call for a systems-thinking approach
to medication adherence: stop blaming the patient. JAMA Intern Med
2018;178:950-1.
8 CJC Open
Volume - 202139. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus
standard-dose clopidogrel and high-dose versus low-dose aspirin in
individuals undergoing percutaneous coronary intervention for acute
coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Lancet 2010;376:1233-43.
40. Mega JL, Hochholzer W, Frelinger AL 3rd, et al. Dosing clopidogrel
based on CYP2C19 genotype and the effect on platelet reactivity in
patients with stable cardiovascular disease. JAMA 2011;306:2221-8.
41. Storey RF, Angiolillo DJ, Bonaca MP, et al. Platelet inhibition with
ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54
trial. J Am Coll Cardiol 2016;67:1145-54.
42. Kim BK, Hong SJ, Cho YH, et al. Effect of ticagrelor monotherapy vs
ticagrelor with aspirin on major bleeding and cardiovascular events in
patients with acute coronary syndrome: the TICO randomized clinical
trial. JAMA 2020;323:2407-16.
43. Sibbing D, Aradi D, Jacobshagen C, et al. Guided de-escalation of an-
tiplatelet treatment in patients with acute coronary syndrome undergoing
percutaneous coronary intervention (TROPICAL-ACS): a randomised,
open-label, multicentre trial. Lancet 2017;390:1747-57.44. Cuisset T, Deharo P, Quilici J, et al. Benefit of switching dual antiplatelet
therapy after acute coronary syndrome: the TOPIC (timing of platelet
inhibition after acute coronary syndrome) randomized study. Eur Heart J
2017;38:3070-8.
45. Gimbel M, Qaderdan K, Willemsen L, et al. Clopidogrel versus ticagrelor
or prasugrel in patients aged 70 years or older with non-ST-elevation
acute coronary syndrome (POPular AGE): the randomised, open-label,
non-inferiority trial. Lancet 2020;395:1374-81.
46. Federal Court. Federal Court Decisions - Eli Lilly. Canada Inc. v. Apotex
Inc, 2018.
47. Teng R, Mitchell P, Butler K. Effect of rifampicin on the pharmacoki-
netics and pharmacodynamics of ticagrelor in healthy subjects. Eur J Clin
Pharmacol 2013;69:877-83.
48. Holmberg MT, Tornio A, Joutsi-Korhonen L, et al. Grapefruit juice
markedly increases the plasma concentrations and antiplatelet effects of
ticagrelor in healthy subjects. Br J Clin Pharmacol 2013;75:1488-96.
49. Teng R, Butler K. A pharmacokinetic interaction study of ticagrelor and
digoxin in healthy volunteers. Eur J Clin Pharmacol 2013;69:1801-8.
